Actively Recruiting
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Led by Innate Pharma · Updated on 2026-01-07
145
Participants Needed
7
Research Sites
218 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a first-in-human, open-label, multicenter, Phase 1 study to evaluate the safety, tolerability and preliminary efficacy of IPH4502 and to determine the recommended Phase 2 dose (RP2D) in advanced solid tumors that are known to express Nectin-4
CONDITIONS
Official Title
Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Histologically confirmed, unresectable, locally advanced or metastatic solid tumors that express Nectin-4
- Prior systemic treatment for locally advanced or metastatic disease with no therapy demonstrating clinical benefit available
- Measurable disease according to RECIST 1.1
- Archival tumor tissue obtained within 4 months before screening or agreement to undergo tumor biopsy at baseline
- Adequate organ and blood function
You will not qualify if you...
- Known or suspected brain metastases
- Active infection or infection requiring systemic treatment
- Presence of clinically significant comorbidities
- History or suspicion of interstitial lung disease at baseline
- Use of systemic corticosteroids or immunosuppressive therapy during IPH4502 treatment
- Thromboembolic event requiring anticoagulation within 14 days prior to first dose
- Significant cardiovascular disease or cardiac repolarization abnormalities
- Symptomatic heart failure or acute coronary syndromes
- Recent major surgery within 28 days or minor surgery within 7 days prior to first dose
- Use of live-attenuated vaccines within 6 weeks before first dose
- Use of systemic corticosteroids or immunosuppressants within 14 days prior to first dose
- Use of moderate or strong CYP 3A4 inhibitors or inducers systemically
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Massachusetts General Hospital - Boston
Boston, Massachusetts, United States, 02114
Actively Recruiting
2
John Theurer Cancer Center
Hackensack, New Jersey, United States, 07601
Actively Recruiting
3
Mount Sinai Tisch Cancer Center
New York, New York, United States, 10029
Actively Recruiting
4
NEXT Oncology - Dallas
Dallas, Texas, United States, 75039
Actively Recruiting
5
NEXT Oncology - Virginia
Fairfax, Virginia, United States, 22031
Actively Recruiting
6
Centre Léon Bérard
Lyon, France, 69008
Actively Recruiting
7
Gustave Roussy Cancer Institute
Villejuif, France, 94805
Actively Recruiting
Research Team
I
Innate Pharma
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here